AbbVie: EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia *EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint *Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, Ill., Nov. 11, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that its two Phase 2